Longevity Health reports unaudited Q1 revenue $663,000, up 8% year-over-year

Longevity Health (XAGE) announced the following business updates: Merger Agreement entered with 20/20 BioLabs: Merger Agreement executed on April 11, 2025, pursuant to which 20/20 is expected to continue as a wholly owned subsidiary of XAGE following merger closing subject to the satisfaction of the conditions set forth in the Merger Agreement. S-4 prospectus filed with the Securities and Exchange Commission on May 8, 2025. Unaudited Q1 sales: XAGE: approximately $663,000 on a full quarter pro forma basis, an increase of 8% over the same period last year. 20/20: approximately $562,000, an increase of 15% over the same period last year. Reverse Stock Split: Completed a 1 for 30 reverse stock split of XAGE’s common stock on May 12, 2025. Stock began trading at split adjusted price on May 14, 2025. Expected Q2 New Product Launches XAGE: expects to launch a medicated cleanser for use in Physicians’ offices and MedSpas. This cleanser will also be marketed to 20/20’s customer base which consists predominantly of firefighters. 20/20: expects to launch a new lab test that measures inflammatory biomarkers in the blood, a key contributor to premature aging and precursor to various skin and health disorders. This test will also be marketed to XAGE’s customer base of physicians and MedSpas. 20/20: announced an initiative with Giant Food at 9 stores in Maryland and Virginia to offer OneTestTM, their multi-cancer test using capillary blood. Giant is also considering expanding the pilot to include a test that spots biomarkers linked to pro-inflammatory foods. Additional Financing XAGE is evaluating options and anticipates announcing a primary investment in Q2 2025.